FcγRs 2 . FcR γ-chain-deficient (Fcer1g −/− ) mice express no functional activating FcγRs but do express the inhibitory FcγRIIB. These mice are protected from IC-mediated inflammation despite the presence of C5a. We hypothesized that one mechanism underlying such protection could be an anti-inflammatory property of IgG ICs suppressing C5a-mediated effector functions.
To test our hypothesis, we injected C5a into the peritoneal cavity of BALB/c wild-type (WT) or Fcer1g −/− mice. As expected, neutrophils were recruited into the peritoneum in both mouse strains (Fig. 1a) . IgG1 is the most abundant isotype of serum antibody in mice. The preferential binding of IgG1 to inhibitory FcγRIIB is considered a protective mechanism to prevent incidental activation of circulating myeloid cells by binding of ICs to activating FcγRs 12 . Intravenous injection of the trinitrophenyl (TNP)-specific IC comprising IgG1 clone 107.3 and TNP-OVA (107.3-IC) 13 30 min before C5a administration reduced C5a-mediated neutrophil migration into the peritoneum in WT and Fcer1g −/− mice but not in FcγRIIB-deficient (Fcgr2b −/− ) mice ( Fig. 1a and Supplementary Fig. 1 ). Monomeric 107.3 antibody did not have an anti-inflammatory effect (data not shown). We have previously shown that the peritoneal inflammation induced by ovalbumin (OVA)-specific ICs is mediated by C5a 11 . Pretreatment with 107.3-IC blocked OVA-IC-induced peritonitis in WT but not Fcgr2b −/− mice, demonstrating a crucial role for FcγRIIB in 107.3-IC-mediated inhibition of C5a-dependent inflammation (Fig. 1b) .
The mechanisms underlying C5aR-mediated extravasation and tissue recruitment of neutrophils involve the β 2 integrin heterodimer CD11b and CD18 (CR3) 14 . C5a upregulated CD11b expression on neutrophils from WT (data not shown) and Fcer1g −/− mice in a dose-dependent manner ( Supplementary Fig. 2 ), and this upregulation was significantly reduced upon 107.3-IC pretreatment and was absent with cells from Fcgr2b −/− mice (Fig. 1c) . 107.3-IC administration also reduced C5a-dependent neutrophil adhesion among cells from Fcer1 −/− but not Fcgr2b −/− mice (Fig. 1d) . Next, we found that 107.3-ICs dose-dependently inhibited C5a-mediated chemotaxis of bone marrow-derived neutrophils and peritoneal macrophages ( Fig. 1e and Supplementary Fig. 3a-d ) from WT and Fcer1g −/− mice but not from Fcgr2b −/− mice. Pharmacological targeting of FcγRIIB with the FcγRIIB-specific blocking antibody Ly17.2 abrogated the inhibitory effect of 107.3-ICs on C5a-mediated neutrophil migration ( Supplementary Fig. 4) . Thus, 107.3-ICs inhibit the functions not only of activating FcγRs 12 but also of complement-mediated acute inflammation. Moreover, we found that 107.3-ICs blocked not only C5aR but also CXCL2-dependent neutrophil migration of WT-and Fcer1g −/− -but not Fcgr2b −/− -derived cells ( Supplementary Fig. 3b,e) , suggesting a more general mechanism of inhibition.
C5aR exerts many of its biological functions through activation of the mitogen-activated protein (MAP) kinases extracellular signal-regulated kinases 1 and 2 (ERK1/2) and the phospholipase C-inositol phosphate pathway, leading to an increase in intracellular calcium release ([Ca 2+ ] i ) 2 . 107.3-ICs blocked the C5a-mediated rise of [Ca 2+ ] i in bone marrow-derived cells from WT and Fcer1g −/− mice but not from Fcgr2b −/− mice (Fig. 1f) . Next, we tested the impact of 107.3-ICs on C5a-mediated ERK1/2 phosphorylation in Gr1 + bone marrow-derived neutrophils (Fig. 1g) . C5a promotes phosphorylation of ERK1/2 in Gr1 + bone marrow-derived neutrophils ( Supplementary  Fig. 5a ), which is inhibited by 107.3-ICs in a dose-dependent manner in bone marrow-derived neutrophils from WT but not Fcgr2b −/− mice ( Fig. 1h and Supplementary Fig. 5b ). This inhibitory effect was similar in magnitude to what we found when C5aR signaling was blocked with the C5aR antagonist A8 ∆71−73 (5 × 10 −5 M) 15 (Fig. 1h) . Taken together, these results demonstrate that IgG1-ICs block C5a-mediated inflammation by an FcγRIIB-dependent mechanism leading to inhibition of both ERK1/2 phosphorylation and intracellular calcium release.
IgG1 IC-mediated coaggregation of FcγRIIB with activating FcγRs negatively regulates immune cell activation. Mechanistically, such coaggregation enables the Src kinase that phosphorylates the immunoreceptor tyrosine-based activation motif (ITAM) in the γ-chain of activating FcγRs to also phosphorylate the immunoreceptor tyrosine-based inhibitory motif (ITIM) within the α-chain of FcγRIIB 12 . The tyrosinephosphorylated ITIM then allows binding and activation of SHIP. Because 107.3-ICs block C5a-mediated chemotaxis of myeloid cells from Fcer1g −/− mice, the effect does not result from classical pairing of activating FcγRs with FcγRIIB. To search for potential new partners of FcγRIIB driving ITIM and SHIP phosphorylation, we focused on dectin-1 (gene symbol Clec7a), as it harbors an ITAMlike motif and is expressed on neutrophils 16 . First, we evaluated the impact of the dectin-1 inhibitor laminarin and the dectin-1 agonist curdlan on the inhibitory effect of 107.3-ICs. In vitro preincubation with laminarin or curdlan largely blocked the inhibitory effects of 107.3-IC inhibitory on C5a-mediated neutrophil migration, indicating that dectin-1 is required (Fig. 2a) . The particulate β-glucan polymer curdlan but not the soluble polymer laminarin promotes rapid internalization of dectin-1 in neutrophils 17 ( Supplementary  Fig. 6 ), suggesting that the surface availability of dectin-1 is crucial for the inhibitory effect of IgG1-IC. We found that 30-40% of Ly-6G hi bone marrow-derived neutrophils express dectin-1. C5aR expression follows the same pattern; that is, about 25-30% of Ly-6G hi neutrophils express dectin-1and C5aR (Fig. 2b) . About 10% of bone marrow-derived neutrophils are C5aR dim dectin-1 − . FcγRIIB is expressed on almost all Ly-6G hi neutrophils (Fig. 2b) . In line with these findings, only Ly6G hi dectin-1 + C5aR + neutrophils migrated toward C5a (Fig. 2c) . 107.3-ICs failed to inhibit C5a-mediated migration of bone marrow-derived neutrophils from dectin-1-deficient (Clec7a −/− ) mice 18 ( Fig. 2d) . C5a-mediated migration was, however, blocked by 107.3-ICs in Clec7a −/− neutrophils retrovirally transduced with the dectin-1B isoform but not with the control vector lacking dectin-1 (ref. 19) ( Fig. 2e and Supplementary Fig. 7 ). Thus, IgG1-ICs require FcγRIIB and dectin-1 to inhibit C5a-mediated effector functions in neutrophils.
To search for the signaling pathways underlying this inhibitory effect of IgG1-ICs, we noted that the inhibitory effect occurred after 1 min and that inhibition of tyrosine phosphorylation by the tyrosine kinase inhibitor genistein completely abrogated the inhibitory effect of IgG1-IC ( Fig. 3a and Supplementary Fig. 8a ). Phosphorylated Src kinases mediate tyrosine phosphorylation of the FcγRIIB-associated ITIM and the ITAM-like motif in dectin-1. We found that the two Src-family kinase inhibitors I and II completely blocked the inhibitory effect of 107.3-ICs on neutrophil (Fig. 3b,c) .
Ligation of dectin-1 results in the phosphorylation of spleen tyrosine kinase (Syk) 20 . Genetic deletion of Syk in inducible Sykdeficient mice 21 and pharmacological targeting by four different Syk kinase inhibitors, R406, piceatannol, BAY 61-3606 or Syk inhibitor, completely reversed the inhibitory effect of IgG1-ICs on C5a-mediated neutrophil chemotaxis (Fig. 3d,e and Supplementary  Figs. 8b-d and 9 ). To further demonstrate that IgG1-IC promotes Syk phosphorylation in a dectin-1-dependent manner, we pulled down phosphorylated Syk with a Syk-binding phosphopeptide 22 in the Clec7a −/− neutrophil cell line transduced with the dectin-1B isoform following 107.3-IC treatment (Supplementary Fig. 8e ). Finally, by confocal microscopy, Syk ( Fig. 10a,b) .
Taken together, these data suggest that IgG1-ICs engage dectin-1, leading to Syk phosphorylation. Tyrosine and Syk phosphorylation downstream of dectin-1 are also linked to tyrosine phosphorylation of the ITIM within FcγRIIB and subsequent SHIP phosphorylation. This pathway then blocks C5a-mediated ERK1/2 phosphorylation and calcium influx crucial for C5a-mediated proinflammatory effector functions.
To identify the mechanism underlying the interaction of IgG1-ICs with dectin-1 and FcγRIIB, we focused on the Fc glycan composition. The N-glycan at Asn297 of the Fc moiety is essential for binding of IgG to FcγRs 23 , the serum collectin mannose-binding lectin 24 and the Values are means ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001.
npg l e t t e r S collectin-related molecule C1q 25 . Dectin-1 recognizes β-1,3-glucans expressed by a broad range of fungal pathogens 26 . However, dectin-1 has not be shown to interact with any Fc glycan. A recent nuclear magnetic resonance analysis demonstrated that Fc glycan is more dynamic and accessible than previously thought 27 . When we determined the N-glycan galactosylation ( Supplementary Fig. 11 Fig. 13a ).
To directly assess the importance of N-glycan galactosylation, we galactosylated or degalactosylated H5 antibody in vitro, yielding a highly galactosylated form (HiGalH5-Ab; Fc glycan galactose content 96.9%) and a degalactosylated form (LoGalH5-Ab; Fc glycan galactose content 8.8%) ( Supplementary Fig. 12 and Supplementary Table 1) . N-glycan composition had no effect on antigen binding (Supplementary Fig. 14) . Fig. 13a-c) . Additional sialylation of highly galactosylated H5 antibody (SialH5) (Supplementary Fig. 12 and Supplementary Table 1 ) did not alter the inhibitory effect (Supplementary Fig. 15a ). Notably, highly galactosylated TNP-specific IgG2a-ICs did not block C5a-mediated chemotaxis in vitro, suggesting that not only the glycan composition but also the IgG isotype, that is, IgG1, contributes to the inhibitory effect ( Supplementary Fig. 15a-c) .
In vivo, HiGalH5-ICs but not LoGalH5-ICs almost completely suppressed C5a-mediated neutrophil recruitment into the peritoneum of WT but not Fcgr2b −/− or Clec7a −/− mice (Fig. 4a) . Further, intravenous administration of curdlan resulted in internalization of dectin-1 on recruited neutrophils and abrogated the inhibitory effect of HiGalH5-ICs on C5a-mediated neutrophil recruitment into the peritoneum (Fig. 4b and Supplementary Fig. 16 ). Previous data suggest a key role for C5 in an experimental model of epidermolysis bullosa acquisita (EBA) 29 , a subepidermal autoimmune blistering disease induced by the transfer of rabbit IgG directed against mouse type VII collagen. We found that C5ar1 −/− mice were protected from the development of EBA (Supplementary Fig. 17 ). HiGalH5-IC but not LoGalH5-IC treatment reduced the development of cutaneous lesions in this model (Fig. 4c,d and Supplementary  Fig. 18 ). HiGal-ICs were not protective in Clec7a −/− mice, confirming the key role of dectin-1 in the protective effect of HiGal-ICs (Supplementary Fig. 19 ). Although dectin-1-deficient humans and mice do not develop spontaneous autoimmunity, our data suggest that dectin-1 may aggravate the inflammatory effector response in autoimmune diseases mediated by C5a. In line with this view, data from experimental models of autoimmune arthritis 30 or encephalitis models 31 point toward a role for dectin-1 as a modulator of autoimmune-driven inflammation. To directly assess whether N-glycan galactosylation drives the association of FcγRIIB and dectin-1, we performed a two-step approach. First, we found that HiGalH5-ICs, H5-ICs and/or LoGalH5-ICs bind FcγRIIB-transfected Chinese hamster ovary cells ( Supplementary  Fig. 20 ) and to recombinant mouse FcγRIIB-Fc ( Supplementary  Fig. 21 ) with similar affinities. In contrast, such ICs do not bind recombinant dectin-1-Fc or a dectin-1-transfected T cell lymphoma cell line (BWZ cells) (data not shown). These data demonstrate that in the absence of FcγRIIB, IgG1-ICs do not bind dectin-1 independent of their galactosylation status. In a second approach, we found by Förster resonance energy transfer (FRET) that HiGalH5-ICs but not LoGalH5-ICs promotes the association of FcγRIIB with dectin-1. Using Cy3-labeled HiGalH5-ICs as donor and an Alexa647-labeled dectin-1-specific antibody as acceptor, we found a FRET efficiency of 20% (Fig. 4e-g and Supplementary Fig. 22) . Notably, we found no FRET when we used Cy3-LoGalH5-ICs as donor or Cy3-HiGalH5-ICs as donor and an Alexa647-labeled Toll-like receptor 4-specific antibody as acceptor (Fig. 4e-g ).
Collectively, our findings demonstrate that high N-glycan galactosylation of IgG1 molecules promotes cooperative signaling of the FcγRIIB with dectin-1, resulting in an inhibitory signaling pathway that blocks the proinflammatory effector functions of the chemoattractant GPCRs C5aR and CXCR2 (Supplementary Fig. 23 ). This mechanism is distinct from the anti-inflammatory properties mediated by sialylation of Fc-linked N-glycans 32 . About 25-35% of Fc glycans from serum IgG are agalactosylated under steady-state conditions 33 . This frequency markedly increases in experimental and human autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease and infections 33 . Thus, the inhibitory effect of highly galactosylated IgG1-ICs may serve as a feedback loop to control complement and chemokine-mediated inflammation in autoimmunity and infection before IgGs switch to the proinflammatory agalactosyl glycoform. This effect may also contribute to the increased incidence of autoimmune phenomena in patients with hypogammaglobulinemia or common variable immunodeficiency 34 .
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Reagents. Monoclonal phycoerythrin (PE)-labeled antibodies to CD11b
(M1/70; 1:100), Ly-6G (1A8; 1:100) and Gr-1 (RB6-8C5; 1:100) were from BD Pharmingen; Alexa488-labeled FcγRIIB-specific antibody (Ly17.2; 1:500) was used as described 11 The goat antibody to C3 was from MP Biomedicals (1:100). The C5a receptor antagonist A8 ∆71−73 has been described elsewhere 15 . The mouse TNP-specific IgG 107.3 was from BD Pharmingen. The mouse TNP-specific IgG1 7B4 was generated by switching the original TNP-specific IgG2a to IgG1 and was produced by transient transfection in HEK293 cells as described 28 . The TNP-specific mouse IgG2a 7B4 was produced from hybridoma cells. Recombinant human C5a (rhC5a), Calcein, 4-hydroxytamoxifen, genistein, piceatannol and R406 were from Sigma-Aldrich. The Src kinase inhibitors I and II and Syk inhibitors and BAY 61-3606 were from Calbiochem. Poly-l-lysine-coated microtiter plates were from Corning. Laminarin, curdlan, stem cell factor (SCF) and β-estradiol were from Sigma-Aldrich. Interleukin-3 (IL-3) and IL-6 were from Peprotech. Mouse FcγRIIB-Fc and CHO-mFcγRIIB were used as described 35 . TNPcoupled BSA was from Biosearch Technology. Supplemented RPMI 1640 medium was from PAA laboratories. Fluoromount-G was from SouthernBiotech. Cy3 Amersham CyDye Antibody Labeling Kit was from GE Healthcare. The polyvinylidene fluoride membrane was from Millipore.
Mice. Female BALB/c or C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Fcer1g −/− and Fcgr2b −/− mice (on BALB/c background) were purchased from Taconic (Laven, Denmark). Dectin-1-deficient mice on the isogenic 129S6/SvEv background (129S6/SvEv.Clec7a −/− ), the C57BL/6 background (C57BL/6.Clec7a −/− ), and the 129S6/SvEv and the C57BL/6 control mice were obtained from our own breeding colonies. Dectin-1 deficiency was also backcrossed for eight generations onto the C57BL/6 genetic background for the production of cell lines (see below). C57BL/6.Clec7a −/− mice were used in peritonitis and in chemotaxis experiments with naive H5, HiGalH5-ICs and LoGalH5-ICs. Inducible Syk-knockout mice have recently been described 21 and were bred at Charles River. All mice were used at 8-12 weeks of age and handled in accordance with the appropriate institutional and national guidelines. All mouse studies were reviewed and approved by local authorities of the Animal Care and Use Committee (Ministerium für Landwirtschaft, Umwelt und ländliche Räume, Kiel, Germany) and performed by certified personnel.
Chemotaxis assay. Bone marrow-derived cells or peritoneal macrophages were resuspended in chemotaxis medium (GBSS containing 2% BSA) at a density of 5 × 10 6 cells ml −1 . The chemoattractants C5a (10 −8 M) or CXCL2 (10 −7 M) were diluted in chemotaxis medium, placed in the bottom wells of a micro Boyden chemotaxis chamber (Neuroprobe) and overlaid with a 3-µm polycarbonate membrane. Then, 50 µl of the cells were placed in the top wells and incubated for 30 min at 37 °C. In some experiments, cells were treated with the indicated concentrations of monomeric IgG1 or IgG1-ICs, IgG2a-ICs, the tyrosine phosphorylation inhibitor genistein (100 µM), the Src-family kinase inhibitors I and II (at 10 µM) or the Syk inhibitors piceatannol (100 µM), R406 (10 µM), Syk inhibitor (10 µM) or BAY 61-3606 (10 µM). Subsequently, the membranes were removed and the cells on the bottom side of the membrane were stained with Diff-Quick. The numbers of migrated cells in five high-power fields were counted, and the number of cells per mm 2 was calculated by computer assisted light microscopy. Results are expressed as the mean value of triplicate samples.
Preparation of TNP-OVA and of TNP-OVA/anti-TNP-OVA IgG1 immune complexes. TNP-OVA complexes were generated as described 13 . Briefly, 1 g of OVA was dissolved in 5 ml of saline and mixed with 500 µl 1 M NaHCO 3 pH 9.6. Then, 50 mg of TNP-ε-aminocaproyl-succinimide ester (OSU) was dissolved in 500 µl DMSO resulting in 100 mg/ml −1 TNP-OSU, which was added to the OVA solution and incubated overnight. The final TNP/OVA ratio was 10:4. TNP-OVA complexes were incubated with TNP-specific IgG1 antibodies at different ratios, and IC formation was determined by Ouchterlony gel diffusion.
C5a-mediated peritoneal inflammation. Mice were injected with C5a (200 nM, 100 µl, i.p.). After 6 h, mice were killed and neutrophil numbers in peritoneal lavage fluid were determined by Diff-Quick staining of Cytospin slides. At least >20 different microscopic fields were evaluated as described 11 .
In some experiments, Ly-6G hi neutrophil numbers were enumerated by flow cytometry using BD True count beads. In some experiments, mice were pretreated intravenously (i.v.) with 107.3-ICs (0.5-50 µg per kg body weight), HiGal H5-ICs or LoGalH5-ICs (50 µg per kg body weight).
Immune complex peritonitis. We used the reverse passive Arthus reaction model. Ovalbumin (OVA, 20 mg per kg body weight; Sigma) was injected i.v., followed by an i.p. injection of OVA-specific rabbit IgG (800 µg per mouse; ICN Biomedicals) as described 11 . Mice were killed 6 h after injury, and the peritoneal cavity was lavaged with 10 ml of PBS. Peritoneal cells were washed once with PBS, and 10 5 cells in 200 µl of PBS were used for preparation of cytospin slides. Neutrophil numbers were evaluated as outlined above. In some experiments, mice were pretreated i.v. with 107.3-ICs at a concentration of 50 µg per kg body weight.
Generation and purification of pathogenic type VII collagen-specific antibodies. Rabbits were immunized with recombinant forms of the NC1 domain of mouse type VII collagen as described 29 . IgGs from immune and normal rabbit sera were purified by affinity chromatography using protein G affinity as previously reported 29 . Isolated IgG was further subjected to affinity purification using recombinant His-tagged fragments of mouse type VII collagen (amino acids 757-967) and Affi-Gel affinity chromatography (Bio-Rad Lab). Reactivity of the isolated IgG fractions was confirmed by immunofluorescence microscopy on mouse skin before in vivo use.
Experimental epidermolysis bullosa acquisita model. Induction of experimental EBA followed published protocols 29 with minor modifications. Briefly, EBA was induced by a total of three subcutaneous injections of 100 µg rabbit type VII collagen-specific, affinity-purified IgG every second day. For treatment, i.v. injections of either PBS, HiGalH5-ICs, LoGalH5-ICs or 107.3-ICs (50 µg per kg body weight) were started on day -1 and repeated on days 3 and 6. Disease progression was evaluated over a time period of 12 d. On days 4, 7 and 12, disease severity was determined and expressed as percentage of body surface area affected by skin lesions, and tail biopsies were taken. On day 12, additional tissue samples were obtained for histological analyses. Disease outcome of the different treatment groups was compared by calculation of the area under the curve (AUC) obtained for the disease progression at the different time points, taking both disease onset and maximal disease activity into account.
Histopathology and immunofluorescence microscopy. Tissue samples were used for histopathological assessment and immunofluorescence microscopy as described previously 29 . To assess morphological skin alteration in diseased mice, sections were stained with H&E. IgG and C3 deposits were detected by direct immunofluorescence microscopy using an FITC-labeled pig anti-rabbit IgG antibody and goat anti-mouse C3 antibody.
Neutrophil preparation. Mice were killed by cervical dislocation under anesthesia. Femurs, tibias and humeri were removed, placed in PBS on ice and subsequently flushed with PBS. More than 80% of cells isolated were polymorphonuclear cells, as defined by Diff-Quick staining, and stained positive for the Ly-6G marker. For Syk depletion in neutrophils from Syk flox/flox mice, cells were cultured in RPMI 1640 medium supplemented with 2 mM l-glutamine, 100 U/ml benzylpenicillin and 0.1 mg/ml dihydrostreptomycin (pen/strep) and 10% FCS in the presence 0.6 µM 4-hydroxy-tamoxifen in ethanol for 48 h. Controls were treated accordingly with ethanol only. Viability was determined by trypan blue exclusion and 7-AAD staining using a BD LSR II flow cytometer. Forty-eight hours of treatment with 4-hydroxy-tamoxifen did not affect the viability of bone marrow-derived neutrophils.
Macrophage preparation. To obtain mouse peritoneal macrophages, the peritoneal cavity was gently flushed with 5 ml of sterile PBS. Peritoneal cells were allowed to adhere on plastic microtiter plates for 4 h at 37 °C. Nonadherent cells were removed by several washing steps with PBS and adherent cells were used for cell migration. Flow cytometric analysis revealed that the majority of adherent cells were F4/80 high CD11b high .
C5a-induced upregulation of CD11b expression. Neutrophils (1 × 10 6 ) were suspended in 100 µl of GBSS buffer containing 2% BSA and treated with C5a (10 nM) at 37 °C for 10 min. Then, cells were placed on ice and washed once with ice-cold PBS. For flow cytometric analysis of CD11b expression, Fc receptors were blocked with 2.4G2 antibody (BD Pharmingen; 1 µg per 10 6 cells in 100 µl of FACS buffer for 30 min on ice). Cells were washed once with PBS and then stained with anti-CD11b antibody conjugated to PE or the corresponding isotype control for 45 min on ice. Data were collected and analyzed on a FACSCalibur (Becton Dickinson) using FCS Express software (Version 3.0).
Complement receptor 3-mediated cell adhesion assay. Complement (iC3b)-coated surfaces were prepared by incubation of poly-l-lysine precoated plates with human IgM (10 µg ml −1 ) and 10% human serum as described 36 . Bone marrow cells were labeled with calcein (2 µg ml −1 ) for 30 min and added to the complement-coated surface ± C5a (0.1, 1 or 10 × 10 −9 M) for 10 min at 37 °C.
In some experiments, calcein-labeled cells were preincubated with 107.3-ICs (0.1 or 1 µg ml −1 ) for 30 min at 37 °C. The fluorescence was measured using an FLX800 Microplate Fluorescence Reader (BioTek Instruments) before and after washing twice with PBS. The percentage adhesion was calculated by dividing the fluorescence signal remaining after washing by that observed before washing.
Increase in intracellular calcium [Ca 2+ ] i . Bone marrow-derived cells were collected and loaded with 5 µM of the Ca 2+ -sensitive fluorophore Fluo-4-AM (Invitrogen) for 30 min. Non-incorporated dye was washed away using PBS. Cells were then gated on Ly-6G hi cells and analyzed on an LSRII flow cytometer (BD). The background signal was recorded for 30 s. Then C5a was added (10 nM), and recording was continued for another 90 s. The increase in [Ca 2+ ] i was calculated by assessment of the Ca 2+ peak using the kinetic plug-in tool of the FlowJo software (Ver. 7.5, Tree Star).
Analysis of ERK1/2 phosphorylation. Bone marrow-derived cells from WT mice were cultured ± 107.3-ICs (0.1 or 1 µg ml −1 ) or the C5aR antagonist A8 ∆71−73 for 30 min at 37 °C. Bone marrow-derived cells were then stimulated with C5a (50 nM) for 1 min and subsequently analyzed for ERK1/2 phosphorylation by intracellular staining with a rabbit anti-phospho-p44/42 MAP kinase antibody. In some experiments, bone marrow-derived cells from Fcgr2b −/− mice were used.
In vitro generation of neutrophils. Bone marrow-derived cells were pooled from the femurs of female C57BL/6.Clec7a −/− mice and were depleted of lineage (lin) + cells using the mouse lineage cell depletion kit (Miltenyi Biotec) as directed by the manufacturer. The lin − cells were prestimulated with IL-3, IL-6 and SCF for 3 d as described 37 before being infected with the pMXs-IP:FL-ERHoxb8 retrovirus 19 and then immediately cultured in SCF and β-estradiol to bias toward neutrophil progenitor outgrowth. Two days after infection cells were selected in 1.5 µg/ml of puromycin for 10 d. Typically, this resulted in the production of stable precursors, termed Myeloid Precursor Hoxb8 from C57BL/6 (MyPH8-B6). The cells were maintained in SCF and β-estradiol as described 37 . MyPH8-B6.Clec7a −/− cells were reconstituted with the dectin-1B isoform with specific (pMXs-IZ:dectin-1B) or empty control (pMXs-IZ) retrovirus as previously described 38 , but using MyPH8 culture medium supplemented with 50 µg/ml of zeocin to maintain the reconstituted cells. Expression of dectin-1B was verified by flow cytometry. For in vitro generation of neutrophils, MyPH8-B6.Clec7a −/− :pMXs-IZ or MyPH8-B6.Clec7a −/− :dectin-1B were washed three times with medium to remove the β-estradiol before differentiation for 4 d in SCF and granulocyte colony-stimulating factor (both 20 ng ml −1 ). By day 4, neutrophils routinely represent 90-98% of the cells present and are identified by flow cytometry as Ly-6B.2 high CD117 low cells and on Cytospin preparations by their typical nuclear morphology.
